Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Lilly says tirzepatide is the first and only approved dual GIP and GLP-1 receptor agonist treatment to reduce excess body weight and maintain weight reduction long-term in combination with diet and exercise
Oct 12 : The FDA greenlit Pfizers Braftovi (encorafenib)/Mektovi (binimetinib) combination for the treatment of adult patients with non-small cell lung cancer (NSCLC) with a BRAF V600E mutation as confirmed by an FDA-approved test
The main adjustment is portion awareness and putting protein first at every meal
March 2025: The plaintiffs in the Ozempic MDL have filed a response to defendants motion from January to dismiss cases
Rare but serious risks of taking metformin include lactic acidosis and flu-like symptoms
Prez-Prez A, Snchez-Jimnez F, Vilario-Garca T, Snchez-Margalet V
